Citation

Angelopoulou E, Bougea A, Paudel YN, Georgakopoulou VE, Papageorgiou SG, Piperi C. Medicina (Lithuania) 2023; 59(6).

Copyright

(Copyright © 2023, Lietuvos Gydytoju Sajunga Lithuania)

DOI

10.3390/medicina59061138

PMID

37374342

PMCID

PMC10301401

Abstract

Background and Objectives: Parkinson's disease (PD) is a clinically heterogeneous disorder with poorly understood pathological contributing factors. Depression presents one of the most frequent non-motor PD manifestations, and several genetic polymorphisms have been suggested that could affect the depression risk in PD. Therefore, in this review we have collected recent studies addressing the role of genetic factors in the development of depression in PD, aiming to gain insights into its molecular pathobiology and enable the future development of targeted and effective treatment strategies.

MATERIALS AND METHODS: we have searched PubMed and Scopus databases for peer-reviewed research articles published in English (pre-clinical and clinical studies as well as relevant reviews and meta-analyses) investigating the genetic architecture and pathophysiology of PD depression.

RESULTS: in particular, polymorphisms in genes related to the serotoninergic pathway (sodium-dependent serotonin transporter gene, SLC6A4, tryptophan hydrolase-2 gene, TPH2), dopamine metabolism and neurotransmission (dopamine receptor D3 gene, DRD3, aldehyde dehydrogenase 2 gene, ALDH2), neurotrophic factors (brain-derived neurotrophic factor gene, BDNF), endocannabinoid system (cannabinoid receptor gene, CNR1), circadian rhythm (thyrotroph embryonic factor gene, TEF), the sodium-dependent neutral amino acid transporter B(0)AT2 gene, SLC6A15), and PARK16 genetic locus were detected as altering susceptibility to depression among PD patients. However, polymorphisms in the dopamine transporter gene (SLC6A3), monoamine oxidase A (MAOA) and B (MAOB) genes, catechol-O-methyltransferase gene (COMT), CRY1, and CRY2 have not been related to PD depression.

CONCLUSIONS: the specific mechanisms underlying the potential role of genetic diversity in PD depression are still under investigation, however, there is evidence that they may involve neurotransmitter imbalance, mitochondrial impairment, oxidative stress, and neuroinflammation, as well as the dysregulation of neurotrophic factors and their downstream signaling pathways.

Language: en

Keywords

Humans; depression; *Amino Acid Transport Systems, Neutral/genetics/therapeutic use; *Parkinson Disease/complications/genetics; Aldehyde Dehydrogenase, Mitochondrial/genetics; BDNF; Catechol O-Methyltransferase/genetics/therapeutic use; Depression/genetics; genetic factors; Genetic Predisposition to Disease; Nerve Growth Factors; Nerve Tissue Proteins/genetics; Parkinson’s disease; Polymorphism, Genetic; Serotonin Plasma Membrane Transport Proteins/genetics; SLC6A4 polymorphism; therapeutic target